Agendia Enters Companion Dx Arena via Collaboration with AstraZeneca, Netherlands Cancer Institute

The diagnostics firm and its partners will focus on accelerating the development of targeted colorectal cancer drugs, though there is also the possibility that Agendia might develop commercial companion diagnostics for specific drugs in AstraZeneca's pipeline.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.